A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer

The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated. The behaviour of VCN-01 in the organism will be assessed, together with the possible benefits of this administration regimen. This study includes adults with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) that has spread to other parts of the body (stage IV) and who have not received prior treatment for pancreatic cancer. Participants will receive three planned doses of VCN-01, gi

Trial Details

NCT ID
NCT07701486
Phase
PHASE1 / PHASE2
Sponsor
Theriva Biologics SL
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)
  • Nab-paclitaxel + Gemcitabine
Locations (sample)
  • Madrid, Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Written informed consent obtained prior to initiating any trial-specific procedures or assessments.
  • Male or female patients aged 18 years or over.
  • Patients with histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic (stage IV) at diagnosis and who have not recei…
  • Patients must be able to receive their first dose of VCN-01 ≤6 weeks after their metastatic pancreatic cancer diagnosis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →